Enanta Pharmaceuticals, Inc.
ENTA Healthcare Biotechnology
Enanta Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended September 2025) was $65.3 million, down 3.42% from fiscal 2024. In the quarter to June 2026, revenue fell 21.6%, EPS grew 21.2% and free cash flow fell 157.5%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
Follow ENTA
Enanta Pharmaceuticals, Inc. (ENTA) EV/Sales
As of 16 October 2026, Enanta Pharmaceuticals, Inc. (ENTA) trades at a EV/Sales of 2.0×. Over the past ten years it has ranged from −2.5× (November 2023) to 17.7× (November 2021); the current reading is higher than 21% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 1.0× | — |
| FY2024 | −0.4× | — |
| FY2023 | −1.9× | — |
| FY2022 | 9.5× | 2.36% |
| FY2021 | 9.3× | 116.25% |
| FY2020 | 4.3× | 4.79% |
| FY2019 | 4.1× | (35.37%) |
| FY2018 | 6.3× | (4.55%) |
| FY2017 | 6.6× | 99.80% |
| FY2016 | 3.3× | 1.04% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 3.6× | 22.58% |
| Mar 2026 | 2.9× | (26.56%) |
| Dec 2025 | 4.0× | 292.16% |
| Sep 2025 | 1.0× | — |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| TTRX Turn Therapeutics Inc. compare | n/m |
| RLMD Relmada Therapeutics, Inc. compare | n/m |
| ENTA Enanta Pharmaceuticals, Inc. | 2.0× |
| CCCC C4 Therapeutics, Inc. compare | 3.6× |
| FENC Adherex Technologies Inc. compare | 5.4× |
| ARCT Arcturus Therapeutics Holdings Inc. compare | 6.1× |
| OBIO Orchestra BioMed Holdings, Inc. compare | 8.5× |
| IRD Opus Genetics, Inc. compare | 31.5× |
| CYPH Cypherpunk Technologies Inc. compare | 311× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)